ADXN Addex Therapeutics Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1574232 · Reporting currency CHF · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CHF | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 | FY2020*2020-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 404,102 | 1.61M | 1.42M | 2.92M | 3.61M |
| R&D expense | 854,305 | 1.19M | 8.24M | 12.84M | 10.37M |
| SG&A expense | 2.31M | 2.67M | 3.74M | 5.82M | 5.75M |
| Operating income | -2.76M | -2.24M | -10.54M | -15.51M | -12.24M |
| Interest expense | 1,609 | 1,644 | 2,068 | 39,146 | 50,460 |
| Pretax income | -4.91M | -2.50M | -10.80M | -15.35M | -12.86M |
| Income tax | 0 | 0 | 0 | 0 | 0 |
| Net income | 7.06M | -10.56M | -20.80M | -15.35M | -12.86M |
| EPS (basic) | 0.07 | -0.14 | -0.46 | -0.45 | -0.48 |
| EPS (diluted) | 0.07 | -0.14 | -0.46 | -0.45 | -0.48 |
| Balance sheet | |||||
| Cash & equivalents | 3.34M | 3.87M | 6.96M | 20.48M | 18.70M |
| Receivables | 15,513 | 110,361 | 416,875 | 164,785 | 68,373 |
| Current assets | 3.54M | 4.23M | 7.83M | 21.94M | 19.49M |
| PP&E, netmay include right-of-use assets (IFRS) | 1,131 | 22,604 | 41,121 | 72,111 | 67,760 |
| Total assets | 10.68M | 4.64M | 8.28M | 22.54M | 20.18M |
| Current liabilities | 802,093 | 2.89M | 3.28M | 4.13M | 3.62M |
| Short-term debt | 0 | 0 | 0 | 0 | 0 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Total debt | 0 | 0 | 0 | 0 | 0 |
| Total liabilities | 1.00M | 3.50M | 3.37M | 5.61M | 5.57M |
| Shareholders' equity | 9.68M | 1.15M | 4.91M | 16.93M | 14.61M |
| Net debt | -3.34M | -3.87M | -6.96M | -20.48M | -18.70M |
| Shares outstanding | 128.29M | 125.20M | 77.13M | 37.90M | 27.12M |
| Cash flow statement | |||||
| Operating cash flow | -5.37M | -7.99M | -16.44M | -14.71M | -12.18M |
| Capital expenditure | 1,273 | 6,842 | 581 | 31,549 | 59,414 |
| Free cash flow | -5.37M | -8.00M | -16.44M | -14.74M | -12.24M |
| Investing cash flow | 4.65M | -6,842 | 2,972 | -30,313 | -59,414 |
| Financing cash flow | 104,918 | 5.26M | 3.10M | 16.40M | 46,399 |
| Stock-based compensation | 502,964 | 1.79M | 3.68M | 1.18M | 1.18M |
Free plan shows the latest 5 periods; Pro shows all 8 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· This company does not report gross profit in XBRL.
· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.